Rasmus Holm-Jorgensen
2022
In 2022, Rasmus Holm-Jorgensen earned a total compensation of $1.7M as Chief Financial Officer at Acrivon Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $136,600 |
|---|---|
| Option Awards | $1,045,702 |
| Salary | $288,231 |
| Stock Awards | $250,375 |
| Total | $1,720,908 |
Holm-Jorgensen received $1M in option awards, accounting for 61% of the total pay in 2022.
Holm-Jorgensen also received $136.6K in non-equity incentive plan, $288.2K in salary and $250.4K in stock awards.
Rankings
In 2022, Rasmus Holm-Jorgensen's compensation ranked 1,994th out of 5,760 executives tracked by ExecPay. In other words, Holm-Jorgensen earned more than 65.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,994 out of 5,760 | 65th |
Division Manufacturing | 1,064 out of 3,136 | 66th |
Major group Chemicals And Allied Products | 456 out of 1,422 | 68th |
Industry group Drugs | 418 out of 1,323 | 68th |
Industry Pharmaceutical Preparations | 303 out of 969 | 69th |
Source: SEC filing on May 1, 2023.
Holm-Jorgensen's colleagues
We found two more compensation records of executives who worked with Rasmus Holm-Jorgensen at Acrivon Therapeutics in 2022.